The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
 
Jarushka Naidoo
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Daiichi Sankyo/Lilly; Elevation Oncology; Kaleido Biosciences; Merck; Mirati Therapeutics; NGM Biopharmaceuticals; Pfizer; Roche/Genentech; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Elevation Oncology; Kaleido Biosciences; Merck; Merck KGaA; Mirati Therapeutics; NGM Biopharmaceuticals; Pfizer; Roche/Genentech; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Douglas Buckner Johnson
Consulting or Advisory Role - Bristol-Myers Squibb; Catalyst Pharmaceuticals; Iovance Biotherapeutics; Mallinckrodt; Merck; Mosaic ImmunoEngineering; Novartis; Oncosec; Pfizer; Targovax
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Charlotte Doran
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Pharmaceutical (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst)
 
Yuexi Wang
Research Funding - Abbvie (Inst); Astellas Oncology (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Kyowa Kirin (Inst); Merck (Inst); Merck KGaA (Inst); Sandoz (Inst)
 
Yan Zhang
Employment - Bristol-Myers Squibb; Janssen
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Trong Kim Le
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sari Hopson
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Brian Dreyfus
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Lincy S. Lal
Employment - ConcertAI; Optum/UnitedHealth Group
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); BMS (Inst); Daiichi Sankyo/UCB Japan (Inst); Gilead Sciences (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Charmy Vyas
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Shay Goldstein
Employment - Apellis Pharmaceuticals (I); Bristol-Myers Squibb
Stock and Other Ownership Interests - Apellis Pharmaceuticals (I); Bristol-Myers Squibb
 
Zara Izadi
Employment - Bristol Myers Squibb Foundation